<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Infection</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5908AE28-52DA-49ED-A8B3-B78D85922CBE"><gtr:id>5908AE28-52DA-49ED-A8B3-B78D85922CBE</gtr:id><gtr:firstName>Gregory</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Towers</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A181FD3D-F540-4D3B-9D83-514FFD53DC26"><gtr:id>A181FD3D-F540-4D3B-9D83-514FFD53DC26</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:surname>Berry</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801172"><gtr:id>203F8153-C427-494C-BDF3-5B187B99AF8B</gtr:id><gtr:title>Correlating gene expression changes and innate immune responses with protective SIV vaccination in cynomolgus macaques</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801172</gtr:grantReference><gtr:abstractText>There are around 33 million people living with HIV/AIDS and around 25 million people have died. There is a desperate need for a protective vaccine but all the recent HIV vaccine trials have failed. This is essentially because we don t really understand how good vaccines work. In monkeys, the only vaccine strategy that works reliably is vaccination with live attenuated virus. This is not acceptable in humans because the attenuated virus could eventually make the vaccinated person ill and they may pass it on to others. This study aims to find out what it is that the vaccine virus does to the vaccinated animals, that makes them immune to a second infection. Based on earlier work at NIBSC we propose that vaccination stimulates innate immunity in the specific cells that the virus infects. This means that the cells infected with the vaccine virus are stimulated to make proteins that protect them and surrounding cells from further infection. We will identify the important genes and proteins by measuring change in their amounts after vaccination. In a parallel approach we will accurately measure amounts of specific proteins known to have anti retroviral properties, comparing vaccinated and unvaccinated animals. In this way we will seek a role for innate immunity in protective vaccination. Once we have identified proteins that appear after vaccination, we will test them for antiviral properties. An important aspect of this study is the close interaction between NIBSC and UCL sponsoring the transfer of technologies and expertise between centres with considerable experience in vaccination studies (NIBSC) and molecular virology and innate immunity (UCL).</gtr:abstractText><gtr:technicalSummary>Around 33 million people are living with HIV/AIDS and around 25 million people have died. There is a great need for a safe, effective human protective vaccine against HIV-1. Vaccination of cynomolgus macaques with live SIV, attenuated by nef mutation, effectively protects against homologous and heterologous challenge. We hypothesise that induction of innate immune antiviral pathways in specific tissues and cells underlies this protection. We propose to identify correlates of protection by measuring gene expression changes in vaccinated animals using DNA microarrays. We will also seek a role for innate immunity by measuring specific, characterised anti-retroviral restriction factors including TRIM5, APOBEC3G/F and tetherin. Once we have identified genes whose expression are stimulated by vaccination we will characterise their molecular mechanism of action, sensitivity to interferon and role in the protective phenotype. We will also seek a role for polymorphism in innate immune factors in outcome after vaccination, collaborating with those investigating a role for MHC polymorphism. A clear understanding of the importance of innate immunity in vaccination against primate lentiviral infection will be invaluable in the search for a protective HIV vaccine strategy in humans.</gtr:technicalSummary><gtr:fund><gtr:end>2012-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-03-03</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>563016</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Laboratory of Molecular Biology (LMB)</gtr:department><gtr:description>Restriction Factor Structure Function</gtr:description><gtr:id>BAEDF414-96CF-4029-8D52-C3581AFA2267</gtr:id><gtr:impact>We have copublished PMIDs 21045130, 20808866, 19767750, 19073742
Collaboration is multidiciplinary in that we are molecular virologists and James is a biophysicist and protein crystallographer</gtr:impact><gtr:outcomeId>bgt3Wm1nspu-1</gtr:outcomeId><gtr:partnerContribution>The James lab has solved crystal structures of restriction factors and viral proteins and performed many biophysical and chemistry experiments allowing us to understand the mechanistic details of restriction factor virus interactions.</gtr:partnerContribution><gtr:piContribution>We have characterised host restriction factor relationships and evolution by collaborating with Leo James at the laboratory for Molecular Biology. Leo solves structures and performs biophysical measurements of protein/protein interactions and we characterise and assay mutant behavior thereby learning mechanistic molecular details of action and evolution.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Mayflower Primary School Tower Hamlets London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B6CB1E8F-753F-48B6-AC50-D056F8C826FC</gtr:id><gtr:impact>Several groups of 30 pupils attended a talk using power point slides and demonstrations as part of meet the parents week. My colleague Richard Milne and I have set up several science demonstrations for children which include demonstrating flu reassortment using bags of tubes with different coloured lids. We demonstrate viral spread using hair gel and glitter. We dress the pupils up in protective lab wear. We also discuss different sizes of pathogens using a slide based demo of the size of bugs (Cells Alive) and compare to preserved tape worms which we have in jars. These demonstrations lead to much discussion of viral infection, viruses and science in general.

The teachers reported that the school was &amp;quot;buzzing with science&amp;quot; after our visit</gtr:impact><gtr:outcomeId>X1Bd1JZswmj</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit to Lab</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>732392C5-5CC3-42B3-B0BC-41EC9DC3FFEF</gtr:id><gtr:impact>Two full day primary school visits (50 pupils per session) to UCL teaching labs where students engaged in a variety of lab activities, including looking at microbes with microscopes, handling specimens such as tapeworms, and precipitating DNA. Students received several short talks about what is science, size big and small, viral life cycles, viral pathogenesis. The children asked a lot of questions about science in general and learned a lot.

The children wrote us letters in which they described their favorite aspect of their day. They also drew pictures or made plasticine models of the microbes that they had seen and discussed</gtr:impact><gtr:outcomeId>iCDo9rK1bCb</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011,2012,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Soho Parish School London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8512B8BB-8943-415D-94BD-1788AC6494F1</gtr:id><gtr:impact>Several groups of 30 pupils attended a talk using power point slides and demonstrations as part of meet the parents week. My colleague Richard Milne and I have set up several science demonstrations for children which include demonstrating flu reassortment using bags of tubes with different coloured lids. We demonstrate viral spread using hair gel and glitter. We dress the pupils up in protective lab wear. We also discuss different sizes of pathogens using a slide based demo of the size of bugs (Cells Alive) and compare to preserved tape worms which we have in jars. These demonstrations lead to much discussion of viral infection, viruses and science in general.

The school reported that the children were very excited by the demos we gave and the school prepared posters in which the children discussed what they had learned via pictures and free text. It was clear that the children had learned a great deal.</gtr:impact><gtr:outcomeId>RiMj6xB2EsW</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gayhurst Primary School Hackney London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9A3D605D-ECEA-4F42-B8E9-A3A5AC4D6809</gtr:id><gtr:impact>30 pupils attend a talk using power point slides and demonstrations as part of meet the parents week. My colleagues and I have set up several science demonstrations for children which include demonstrating flu reassortment using bags of tubes with different coloured lids. We demonstrate viral spread using hair gel and glitter. We dress the pupils up in protective lab wear. We also discuss different sizes of pathogens using a slide based demo of the size of bugs (Cells Alive) and compare to preserved tape worms which we have in jars. These demonstrations lead to much discussion of viral infection, viruses and science in general.

The Gayhurst Science Club requested a visit to the labs which we arranged.</gtr:impact><gtr:outcomeId>SaTzsqitC9w</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009,2010,2011,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit to Carlton Primary School (Camden)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>11565D2F-FB04-4E9C-AD93-04BA709759E9</gtr:id><gtr:impact>Pupils received talks using power point slides and science demonstrations on common viruses/pathogens, followed by discussions.</gtr:impact><gtr:outcomeId>56e0337c9323f0.89261989</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary Science Fair</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>376C9168-4AED-4508-B449-FC2B81A7A649</gtr:id><gtr:impact>70- 100 adults and children attended each of 3 workshops with enthusiastic audience participation and there was a constant stream of interest at our stall where visitors could learn how to pipette, how to count virus particles to small to see and make their own viruses out of plasticine.

We received inquiries from many parents wanting us to visit their children's schools with our workshop</gtr:impact><gtr:outcomeId>qw4SKD1gSXL</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ucl.ac.uk/LMCB/lmcb-takes-lead-mrc-centenary-celebrations-ucl and http://www.ucl.ac.uk/lmcb/mrcucl-centenary-science-fair</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit to Bridge Academy (Hackney)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>79FB3D23-AFA1-4B21-87FD-050B3D407DE0</gtr:id><gtr:impact>Full day visit to Bridge Academy, Hackney. Back-to-back sessions with 14/15 year olds to discuss viruses, Ebola and discovery.</gtr:impact><gtr:outcomeId>56e03337ebad97.48756584</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2121162</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Senior Biomendical Research Fellowship - Second Renewal</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>08CAFDCA-E8E2-4FE1-9729-93B6063A7FB4</gtr:id><gtr:outcomeId>56e0292f4c00a3.70319380</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Bench to Bedside PhD Studentship - Hataf Khan</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6CADD140-7612-4004-BBF2-ACEE7C3C4FB8</gtr:id><gtr:outcomeId>56e02aa6e6c582.52202718</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>182308</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Senior Biomedical Research Fellowship Enhancement</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>31E04E0B-CE37-441D-B8EB-3D3515DAFACB</gtr:id><gtr:outcomeId>CjzdYsSmg9E</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1559842</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Senior Research Fellowship in basic biomedical science</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>DEC62433-223B-4D87-B7A1-F1B6A5D686C3</gtr:id><gtr:outcomeId>JU9NVmseyTg0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>National Institute of Health Research UCL/UCLH Biomedical Research Centre Grant (coapplicant with Dr Waseem Qasim)</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>EF24CC46-C6BF-4D10-BD35-9B66D1420EBC</gtr:id><gtr:outcomeId>YqLrqxc2aAX</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2121162</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Senior Biomendical Research Fellowship - Second Renewal</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>EBE32FA6-907D-433A-B749-1DF2D075915F</gtr:id><gtr:outcomeId>56e0292fbead83.32649679</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>105000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Public Health England PhD Studentship - Claire Kerridge [Co-Supervisor]</gtr:description><gtr:fundingOrg>Public Health England</gtr:fundingOrg><gtr:id>711A8234-0EF3-4E24-BAD6-3B7614EC20D1</gtr:id><gtr:outcomeId>56e03664c77cb2.25975101</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>112375</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>National Institute for Health Research Grant</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>A96B6D46-98AF-4749-8AC3-BB9CD8CED53A</gtr:id><gtr:outcomeId>ENbkSKoS4pU</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>163704</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Sponsor of American Foundation for AIDS Research (AMFAR) Fellowship to Jane Rasaiyaah</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>amfAR, The Foundation for AIDS Research</gtr:fundingOrg><gtr:id>C9934154-7011-493D-A179-11E01089ED1A</gtr:id><gtr:outcomeId>56e0357fa133e2.35851132</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Bench to Bedside PhD Studentship - Richard Miles</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E4742DAB-89E3-45BA-9FBA-EACF4F60CD7F</gtr:id><gtr:outcomeId>56e02a696e4bc1.98155816</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Confidence in Comcept Award (coapplicant with Prof David Selwood)</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>383F686E-D31C-4D5B-A76D-2B2DEC3DA39B</gtr:id><gtr:outcomeId>F85KzUqt8AF</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>192141</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>UCLH/UCL Comprehensive Biomedical Research Centre Project Grant</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>90BE18C9-A705-4084-9F8F-449A2A289250</gtr:id><gtr:outcomeId>56e035e831fc68.61677896</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2158924</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ERC Advanced Grant (coapplicant with Prof David Selwood)</gtr:description><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:id>6BB28FBB-764A-4669-8129-58154273E784</gtr:id><gtr:outcomeId>LUa7rfojcii</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>572292</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0BC50452-065B-415E-A08E-E1D830590D5A</gtr:id><gtr:outcomeId>56e034fbf2a304.34679044</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>54996</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCL Buisness Proof of Concept Award (Coapplicant with Prof David Selwood)</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>B6EF7F5E-157B-4D5E-9C1F-B8F1941F90AC</gtr:id><gtr:outcomeId>fjgJ481q7Rk</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>59387</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCL Therapeutic Innovation Fund Grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>7DD9909A-2980-41CE-B193-5662B28B8FD2</gtr:id><gtr:outcomeId>56e02988716531.55545373</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A specific chemical formula for the treatment of AIDS</gtr:description><gtr:grantRef>G0801172</gtr:grantRef><gtr:id>F1606F7C-AA48-4390-81BA-15DCDA2A2F3D</gtr:id><gtr:impact>Published in Nature. http://www.nature.com/nature/journal/vaop/ncurrent/full/nature12769.html</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>agUh89sPXF7</gtr:outcomeId><gtr:patentId>GB1303681.9</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>A cyclosporin derivative for use in the treatment of HIV/AIDS</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A cyclosporin derivative for the treatment of specific viral diseases.</gtr:description><gtr:grantRef>G0801172</gtr:grantRef><gtr:id>667EF3D9-4298-4BF7-A67F-25BF939A0BCA</gtr:id><gtr:impact>This has been published in nature. http://www.nature.com/nature/journal/vaop/ncurrent/full/nature12769.html</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>c1iQSNytZvc</gtr:outcomeId><gtr:patentId>GB1303685.0</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>A cyclosporin derivative for use in the treatment of HIV-1, Influenza virus, human cytomegalovirus (hCMV) or hepatitus C virus (HCV)</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National Expert Panel on New and Emerging Infections XMRV subgrioup</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>9D652692-F2AD-4607-A300-25F84A472039</gtr:id><gtr:impact>XMRV can infect humans but there is currently no evidence that it causes human disease
Development of a robust diagnostic tool to accurately detect infection is a priority for further investigation of this infection

Further work is required to investigate tissue tropism and pathogenicity, epidemiology of infection and whether this infection is of any public health significance

On the evidence before the Group, no public health action is required at this time</gtr:impact><gtr:outcomeId>YQ6bu914cQP</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E29D8FD5-570B-4957-93A3-80AC5D6F10DA</gtr:id><gtr:title>Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f25e8a22839c8eaf9492900e3ab52a36"><gtr:id>f25e8a22839c8eaf9492900e3ab52a36</gtr:id><gtr:otherNames>Dietrich I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>C6hNebi4wh3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>655597EF-B2D5-4A0C-9FCA-087320332A8B</gtr:id><gtr:title>Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21).</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c71af6e6a5f6449faafda0c5b494a1f3"><gtr:id>c71af6e6a5f6449faafda0c5b494a1f3</gtr:id><gtr:otherNames>Mallery DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>HsKQDDEt34e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5813799-0D46-4E24-960A-A76A49E397A9</gtr:id><gtr:title>Truncation of TRIM5 in the Feliformia explains the absence of retroviral restriction in cells of the domestic cat.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5127c337c4d35c97966a996e685b8462"><gtr:id>5127c337c4d35c97966a996e685b8462</gtr:id><gtr:otherNames>McEwan WA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>swaDkNcaqQB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0D08B18-7665-4D1D-B199-43F05F66D4DB</gtr:id><gtr:title>TRIM5a requires Ube2W to anchor Lys63-linked ubiquitin chains and restrict reverse transcription.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4163edd090b7f7934101c6c7f3ffd2b9"><gtr:id>4163edd090b7f7934101c6c7f3ffd2b9</gtr:id><gtr:otherNames>Fletcher AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>56e0255048de14.87342566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5476CF6-17ED-412F-A0A1-3079FFA2585B</gtr:id><gtr:title>Diverse HIV viruses are targeted by a conformationally dynamic antiviral.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6994fc2e6e840b1c3dc3b989e831439"><gtr:id>d6994fc2e6e840b1c3dc3b989e831439</gtr:id><gtr:otherNames>Caines ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>pm_13996_26_22407016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C51B1DC5-658A-4512-81E7-5A9835DCF1DF</gtr:id><gtr:title>HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b80e4206e65c27027c5eb4c5816ed08"><gtr:id>2b80e4206e65c27027c5eb4c5816ed08</gtr:id><gtr:otherNames>Schaller T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_13996_26_22174692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDC42B4D-2DE1-4BDD-8DD9-C2AC4A40BDEE</gtr:id><gtr:title>A model for cofactor use during HIV-1 reverse transcription and nuclear entry.</gtr:title><gtr:parentPublicationTitle>Current opinion in virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d849bcff7512ae0e8f595615237a927"><gtr:id>7d849bcff7512ae0e8f595615237a927</gtr:id><gtr:otherNames>Hilditch L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1879-6257</gtr:issn><gtr:outcomeId>56e024b2c164b8.58949821</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA3370A9-CD4A-4158-B2E4-F09187D1947A</gtr:id><gtr:title>Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a115fb22ae8b5eb1d761afe50087d24"><gtr:id>9a115fb22ae8b5eb1d761afe50087d24</gtr:id><gtr:otherNames>McCormick AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>odR7z2YgdVT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC8002C1-3B7F-455E-BC1C-11A45E71FA0B</gtr:id><gtr:title>Lentiviral gene therapy against human immunodeficiency virus type 1, using a novel human TRIM21-cyclophilin A restriction factor.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f89c7b4622f2153cac81da53204ade0e"><gtr:id>f89c7b4622f2153cac81da53204ade0e</gtr:id><gtr:otherNames>Chan E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>pm_13996_26_22909012</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>961CC09E-1E70-4E1C-BD13-ECB48F4D512E</gtr:id><gtr:title>Diversity of TRIM5a and TRIMCyp sequences in cynomolgus macaques from different geographical origins.</gtr:title><gtr:parentPublicationTitle>Immunogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6ba1b9e95629587f1143575d6b64393"><gtr:id>f6ba1b9e95629587f1143575d6b64393</gtr:id><gtr:otherNames>Berry NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0093-7711</gtr:issn><gtr:outcomeId>pm_13996_26_22124667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E1F8CFD-9EC3-46D6-9463-63B4EAD1B23F</gtr:id><gtr:title>A tail of Tetherin: how pandemic HIV-1 conquered the world.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1468a3c79a930345b1162a38bc32d1aa"><gtr:id>1468a3c79a930345b1162a38bc32d1aa</gtr:id><gtr:otherNames>Gupta RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn><gtr:outcomeId>qTQ7Gf1Ztme</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8061B515-D13F-4A42-A708-E56AED885ECC</gtr:id><gtr:title>HLA-specific intracellular epitope processing shapes an immunodominance pattern for HLA-B*57 that is distinct from HLA-B*58:01.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5c2d35d76a3ff3436246776122a7aa9"><gtr:id>f5c2d35d76a3ff3436246776122a7aa9</gtr:id><gtr:otherNames>Kl?verpris HN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_13996_26_23864640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6FDE14C-68F8-483F-B6CE-02BA47F12630</gtr:id><gtr:title>Porcine endogenous retroviruses PERV A and A/C recombinant are insensitive to a range of divergent mammalian TRIM5alpha proteins including human TRIM5alpha.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae44d82633c36fa9eba6e8c8a9005700"><gtr:id>ae44d82633c36fa9eba6e8c8a9005700</gtr:id><gtr:otherNames>Wood A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>PN4YUUDZgbQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A428C8C9-1710-4988-AC2F-597B0893D6A6</gtr:id><gtr:title>Early biodistribution and persistence of a protective live attenuated SIV vaccine elicits localised innate responses in multiple lymphoid tissues.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02766ea99fdc02271ba31905900e4123"><gtr:id>02766ea99fdc02271ba31905900e4123</gtr:id><gtr:otherNames>Ferguson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_55faa1aa1e336082</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1CBB6F2-F14C-4504-98E8-3331C7FCC44B</gtr:id><gtr:title>SAMHD1-dependent retroviral control and escape in mice.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f73bda9f22c7c74fa4a798aa3795187"><gtr:id>9f73bda9f22c7c74fa4a798aa3795187</gtr:id><gtr:otherNames>Rehwinkel J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>pm_13996_26_23872947</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFD21317-3B8F-433B-893F-D84F733753B8</gtr:id><gtr:title>No evidence of XMRV or related retroviruses in a London HIV-1-positive patient cohort.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0788e79a32e1e1b065a44e20d7ea9c5"><gtr:id>f0788e79a32e1e1b065a44e20d7ea9c5</gtr:id><gtr:otherNames>Gray ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>LaSepeL8Cdf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0513788-2154-4675-A003-E6A8C1FDA940</gtr:id><gtr:title>The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/044f5e57988afec3522ce0a8b7ff48fe"><gtr:id>044f5e57988afec3522ce0a8b7ff48fe</gtr:id><gtr:otherNames>Pardieu C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>dAffjCsMEa4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B546CC1-129A-40F4-92AA-31B036C93F71</gtr:id><gtr:title>HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ede923f969c5ec692b719203d38f9dc6"><gtr:id>ede923f969c5ec692b719203d38f9dc6</gtr:id><gtr:otherNames>Ocwieja KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>qN4PeA1L1Be</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD122088-D3BE-4718-86A8-B54DE0FE80A1</gtr:id><gtr:title>Tetherin restricts herpes simplex virus 1 and is antagonized by glycoprotein M.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16e46d4f7f3d0fd5771d96152a22af04"><gtr:id>16e46d4f7f3d0fd5771d96152a22af04</gtr:id><gtr:otherNames>Blondeau C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56e0254f6d6b48.32113825</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3807C493-A4E8-4CB6-8DE7-E5F1C9060C54</gtr:id><gtr:title>Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd8773027f8192fe964ca758e49a370"><gtr:id>3dd8773027f8192fe964ca758e49a370</gtr:id><gtr:otherNames>Berry N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13996_26_21853072</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B772005A-C13C-4817-B190-D6D4ED060B69</gtr:id><gtr:title>Conformational adaptation of Asian macaque TRIMCyp directs lineage specific antiviral activity.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5535e5b095530624beba13046aa94cd9"><gtr:id>5535e5b095530624beba13046aa94cd9</gtr:id><gtr:otherNames>Ylinen LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>qGApW7EAonY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A04B84FA-23A1-4525-AF79-07CA2A8201E2</gtr:id><gtr:title>TRIM22 inhibits influenza A virus infection by targeting the viral nucleoprotein for degradation.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67f6a49d89030d49da8ab007e4a081ae"><gtr:id>67f6a49d89030d49da8ab007e4a081ae</gtr:id><gtr:otherNames>Di Pietro A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_13996_26_23408607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDCC4858-6AA1-4256-A0E1-514443EA207A</gtr:id><gtr:title>Disease-associated XMRV sequences are consistent with laboratory contamination.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d0e4078101e2913852def3cc79eff29"><gtr:id>0d0e4078101e2913852def3cc79eff29</gtr:id><gtr:otherNames>Hu? S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>96CFC021_296CFC021_2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29D1CEC9-6573-4833-B772-F36AC24F3AE9</gtr:id><gtr:title>Inhibition of retroviral replication by members of the TRIM protein family.</gtr:title><gtr:parentPublicationTitle>Current topics in microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4163edd090b7f7934101c6c7f3ffd2b9"><gtr:id>4163edd090b7f7934101c6c7f3ffd2b9</gtr:id><gtr:otherNames>Fletcher AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0070-217X</gtr:issn><gtr:outcomeId>pm_13996_26_23686231</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9339E5D6-13B4-403A-B00B-9ADB03032901</gtr:id><gtr:title>Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2046d415c257b2fe0d1ecb7aa072c4d1"><gtr:id>2046d415c257b2fe0d1ecb7aa072c4d1</gtr:id><gtr:otherNames>Parry CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>maCria1nVS1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9EFBEE8-02B9-4DC0-83C3-4802EDFB7483</gtr:id><gtr:title>Endoplasmic reticulum degradation-enhancing a-mannosidase-like protein 1 targets misfolded HLA-B27 dimers for endoplasmic reticulum-associated degradation.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/439b5ba9e59cc5db5573c4d16339e4ab"><gtr:id>439b5ba9e59cc5db5573c4d16339e4ab</gtr:id><gtr:otherNames>Guiliano DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>56e0255028cad7.03913861</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6116A121-B16E-4011-96FD-485403A827CC</gtr:id><gtr:title>Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9db46c5b7405794c0889d48fee503e50"><gtr:id>9db46c5b7405794c0889d48fee503e50</gtr:id><gtr:otherNames>Petit SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>ZQFKbj4WVYT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3498DF54-6072-409C-9E6A-116D177CA290</gtr:id><gtr:title>Vpx complementation of 'non-macrophage tropic' R5 viruses reveals robust entry of infectious HIV-1 cores into macrophages.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/292b41fa56f474420b9e8bde21def9a9"><gtr:id>292b41fa56f474420b9e8bde21def9a9</gtr:id><gtr:otherNames>Mlcochova P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>56e0254fd922b4.91373288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FD42A9F-6A2A-45DA-94FF-83D0819ABAC1</gtr:id><gtr:title>Upregulation of TRIM5a gene expression after live-attenuated simian immunodeficiency virus vaccination in Mauritian cynomolgus macaques, but TRIM5a genotype has no impact on virus acquisition or vaccination outcome.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d601c726d34be556fecbbd27cb08186"><gtr:id>2d601c726d34be556fecbbd27cb08186</gtr:id><gtr:otherNames>Mattiuzzo G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_13996_26_23152371</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1731EDEA-649B-455F-900F-3E1547934F10</gtr:id><gtr:title>Adherent human alveolar macrophages exhibit a transient pro-inflammatory profile that confounds responses to innate immune stimulation.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95729c2d3a47703ec5f65134a7553513"><gtr:id>95729c2d3a47703ec5f65134a7553513</gtr:id><gtr:otherNames>Tomlinson GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13996_26_22768282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FD68CE8-1770-4CC7-822D-40ACD29C0C92</gtr:id><gtr:title>No evidence of XMRV in prostate cancer cohorts in the Midwestern United States.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cac4a32cea8345e9a184ca5f2dc240f"><gtr:id>5cac4a32cea8345e9a184ca5f2dc240f</gtr:id><gtr:otherNames>Sakuma T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>RNK8H7vPatE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6F204A3-1B99-4B47-8B63-E4A8FEE1E100</gtr:id><gtr:title>Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1468a3c79a930345b1162a38bc32d1aa"><gtr:id>1468a3c79a930345b1162a38bc32d1aa</gtr:id><gtr:otherNames>Gupta RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>mhb2rKxm8yB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76556338-FF16-4FCD-9448-FF4BEFE6EF9A</gtr:id><gtr:title>Active site remodeling switches HIV specificity of antiretroviral TRIMCyp.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a6beffb1b3dfaecfccd9f955cc3b231"><gtr:id>2a6beffb1b3dfaecfccd9f955cc3b231</gtr:id><gtr:otherNames>Price AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>kptoawAquR1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76270F4C-D623-4C8F-B2F4-779E21DCD10F</gtr:id><gtr:title>Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1468a3c79a930345b1162a38bc32d1aa"><gtr:id>1468a3c79a930345b1162a38bc32d1aa</gtr:id><gtr:otherNames>Gupta RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>NheKTrq4bG5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4898755-49E9-40BA-8FCF-E87FDCD0E283</gtr:id><gtr:title>Early antigen presentation of protective HIV-1 KF11Gag and KK10Gag epitopes from incoming viral particles facilitates rapid recognition of infected cells by specific CD8+ T cells.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5c2d35d76a3ff3436246776122a7aa9"><gtr:id>f5c2d35d76a3ff3436246776122a7aa9</gtr:id><gtr:otherNames>Kl?verpris HN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_13996_26_23255798</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EDDFD41-FD88-4FB2-964C-9DDEDF4F0E3D</gtr:id><gtr:title>Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha.</gtr:title><gtr:parentPublicationTitle>Trends in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a22858f758e08c8666a044713dd48bb7"><gtr:id>a22858f758e08c8666a044713dd48bb7</gtr:id><gtr:otherNames>Huthoff H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0966-842X</gtr:issn><gtr:outcomeId>pm_13996_16_18976920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACAFB007-DC7F-47CD-867D-B95B81F4AE85</gtr:id><gtr:title>HIV-1 infection of macrophages is dependent on evasion of innate immune cellular activation.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfe8677cb938dc1232570dc209d4c71e"><gtr:id>cfe8677cb938dc1232570dc209d4c71e</gtr:id><gtr:otherNames>Tsang J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>noPAz9D6sqW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C424BE46-DFC2-4359-9680-5202D4ACC2AC</gtr:id><gtr:title>Identification of a RELIK orthologue in the European hare (Lepus europaeus) reveals a minimum age of 12 million years for the lagomorph lentiviruses.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/303c119beb542abcde81d023f6f3fef2"><gtr:id>303c119beb542abcde81d023f6f3fef2</gtr:id><gtr:otherNames>Keckesova Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>pm_13996_16_19070882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>829129AF-9463-42FB-81B2-CAE3CF13D183</gtr:id><gtr:title>Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1468a3c79a930345b1162a38bc32d1aa"><gtr:id>1468a3c79a930345b1162a38bc32d1aa</gtr:id><gtr:otherNames>Gupta RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>BA1043BD312</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>674A5B99-18A2-4FFF-9D11-B1A97BE43296</gtr:id><gtr:title>Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38218caebb35ad6a218ed8f5d172be55"><gtr:id>38218caebb35ad6a218ed8f5d172be55</gtr:id><gtr:otherNames>Warne J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>56e025506a3ef5.22386662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFEE27C4-F96D-4AD0-9512-3D56D38F6705</gtr:id><gtr:title>Gene therapy strategies to exploit TRIM derived restriction factors against HIV-1.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f89c7b4622f2153cac81da53204ade0e"><gtr:id>f89c7b4622f2153cac81da53204ade0e</gtr:id><gtr:otherNames>Chan E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>56e0254fbc0419.04384092</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD1DF81F-F493-4BDF-9F97-569DD72A7A4A</gtr:id><gtr:title>Ovine TRIM5a can restrict visna/maedi virus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5657dc368990f3b9334380f063e243aa"><gtr:id>5657dc368990f3b9334380f063e243aa</gtr:id><gtr:otherNames>J?uregui P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_13996_26_22696640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B79D58B1-B7E3-45BA-965B-B2C74EDA100C</gtr:id><gtr:title>Hare TRIM5a restricts divergent retroviruses and exhibits significant sequence variation from closely related lagomorpha TRIM5 genes.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4163edd090b7f7934101c6c7f3ffd2b9"><gtr:id>4163edd090b7f7934101c6c7f3ffd2b9</gtr:id><gtr:otherNames>Fletcher AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>E2YwNMNGvrF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BD7E39D-AF9E-4F04-B1C5-411AB2A2A015</gtr:id><gtr:title>Phylogenetic analysis of murine leukemia virus sequences from longitudinally sampled chronic fatigue syndrome patients suggests PCR contamination rather than viral evolution.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1726215f97cf2a56089d86c8d135545"><gtr:id>d1726215f97cf2a56089d86c8d135545</gtr:id><gtr:otherNames>Katzourakis A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>oXvLLbNvJm7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7B870F3-89B5-4E0E-B4AA-7EC86B3DE236</gtr:id><gtr:title>Interactions between HIV-1 and the cell-autonomous innate immune system.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9d8dc102629560a2c32a6e4c03990a0"><gtr:id>c9d8dc102629560a2c32a6e4c03990a0</gtr:id><gtr:otherNames>Towers GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn><gtr:outcomeId>56e0255006f4b0.85399448</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE16703F-F840-4403-A7D7-8EC0E0850DF5</gtr:id><gtr:title>Analysis of XMRV integration sites from human prostate cancer tissues suggests PCR contamination rather than genuine human infection.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b5ae5ab08033b049c445101cf1d5a87"><gtr:id>9b5ae5ab08033b049c445101cf1d5a87</gtr:id><gtr:otherNames>Garson JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>XkwAfrtr9BN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3CF9797-B5E7-49B9-B7F7-7D50BA1ACE87</gtr:id><gtr:title>HIV-1 capsid undergoes coupled binding and isomerization by the nuclear pore protein NUP358.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c660668f7b12ef3922555af6a0e45cc5"><gtr:id>c660668f7b12ef3922555af6a0e45cc5</gtr:id><gtr:otherNames>Bichel K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>pm_13996_26_23902822</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E526360E-CA14-4E54-93AA-A4BC2D5DE75A</gtr:id><gtr:title>CPSF6 defines a conserved capsid interface that modulates HIV-1 replication.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a6beffb1b3dfaecfccd9f955cc3b231"><gtr:id>2a6beffb1b3dfaecfccd9f955cc3b231</gtr:id><gtr:otherNames>Price AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_13996_26_22956906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CA639BE-7B5D-4A97-A4D6-00D7DED37665</gtr:id><gtr:title>Positive Selection Analysis of Overlapping Reading Frames Is Invalid.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fc0ca3e5fa5bff6c18e75168f2221af"><gtr:id>9fc0ca3e5fa5bff6c18e75168f2221af</gtr:id><gtr:otherNames>Monit C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>56e024b2e88cc1.34936058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01EEED79-1A16-4750-9E8D-3681B38BE5A9</gtr:id><gtr:title>HIV-1 evades innate immune recognition through specific cofactor recruitment.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34c1e8ababaaac31f24b1fb218be5bbb"><gtr:id>34c1e8ababaaac31f24b1fb218be5bbb</gtr:id><gtr:otherNames>Rasaiyaah J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>56e0254f951c34.82819938</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71FF4287-C4CA-4B92-BD7A-50F1454B2DDF</gtr:id><gtr:title>Innate immunity against HIV: a priority target for HIV prevention research.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6b6ae8702947976cd643c36a0d0bf5d"><gtr:id>f6b6ae8702947976cd643c36a0d0bf5d</gtr:id><gtr:otherNames>Borrow P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>BLca34H2zKb</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801172</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>